Enliven Therapeutics Inc
NASDAQ:ELVN
Enliven Therapeutics Inc
NASDAQ:ELVN
Price:
20.2 USD
-1.17%
Updated:
Jun 7, 2024
Balance Sheet
Balance Sheet Decomposition
Enliven Therapeutics Inc
Enliven Therapeutics Inc
| Current Assets | 337.2m |
| Cash & Short-Term Investments | 320.5m |
| Other Current Assets | 16.7m |
| Non-Current Assets | 5.6m |
| PP&E | 924k |
| Other Non-Current Assets | 4.7m |
| Current Liabilities | 25m |
| Accounts Payable | 2.7m |
| Accrued Liabilities | 12.3m |
| Other Current Liabilities | 10m |
| Non-Current Liabilities | 34k |
| Other Non-Current Liabilities | 34k |
Balance Sheet
Enliven Therapeutics Inc
Enliven Therapeutics Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
10
|
7
|
5
|
48
|
48
|
76
|
100
|
|
| Cash Equivalents |
10
|
7
|
5
|
48
|
48
|
76
|
100
|
|
| Short-Term Investments |
0
|
0
|
24
|
41
|
42
|
0
|
153
|
|
| Other Current Assets |
1
|
0
|
2
|
2
|
2
|
2
|
13
|
|
| Total Current Assets |
10
|
8
|
31
|
90
|
93
|
78
|
266
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
1
|
2
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
2
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
0
|
0
|
4
|
5
|
|
| Total Assets |
10
N/A
|
8
-25%
|
33
+332%
|
91
+173%
|
94
+3%
|
83
-11%
|
272
+226%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
1
|
2
|
2
|
2
|
3
|
1
|
|
| Accrued Liabilities |
0
|
1
|
3
|
4
|
5
|
7
|
15
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
10
|
|
| Total Current Liabilities |
1
|
2
|
4
|
6
|
7
|
10
|
26
|
|
| Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Liabilities |
1
N/A
|
2
+23%
|
4
+139%
|
6
+46%
|
8
+19%
|
10
+36%
|
26
+150%
|
|
| Equity | ||||||||
| Common Stock |
24
|
32
|
78
|
0
|
0
|
150
|
0
|
|
| Retained Earnings |
20
|
31
|
55
|
96
|
148
|
83
|
154
|
|
| Additional Paid In Capital |
4
|
5
|
6
|
181
|
234
|
6
|
400
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
9
N/A
|
6
-33%
|
29
+393%
|
84
+192%
|
86
+2%
|
73
-15%
|
246
+237%
|
|
| Total Liabilities & Equity |
10
N/A
|
8
-25%
|
33
+332%
|
91
+173%
|
94
+3%
|
83
-11%
|
272
+226%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
4
|
4
|
4
|
4
|
7
|
4
|
41
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
